Livmarli (maralixibat) has been approved in Japan for the treatment of itching in people with Alagille syndrome and progressive familial intrahepatic cholestasis (PFIC),…
News
Precision Biosciences has been given the go-ahead to expand a Phase 1 clinical trial testing PBGENE-HBV, its gene-editing therapy for chronic hepatitis…
CHOLANGITIS
News2nd-line PBC treatment options call for personalized care: Analysis
Among second-line treatments for primary biliary cholangitis (PBC), Iqirvo (elafibranor) may work better than Livdelzi (seladelpar) at reducing markers of liver damage, while Livdelzi…
CHOLESTASIS
NewsNew ABCB4 mutation found to be cause of PFIC3 in young woman
A new mutation in the ABCB4 gene was found to cause progressive familial intrahepatic cholestasis (PFIC) type 3 in a young woman, a case…
FATTY LIVER DISEASE
NewsLiverMultiScan may lessen need for biopsy in assessing MASLD
Perspectum‘s MRI-based LiverMultiScan improves the diagnostic rate of metabolic dysfunction-associated steatotic liver disease (MASLD) — a form of fatty liver disease —…
BILIARY ATRESIA
NewsCytokine levels may predict Kasai procedure outcome in biliary atresia
Blood levels of certain immune signaling molecules called cytokines may help to predict the likelihood of a successful outcome with the…
The first patient has been enrolled in ECLIPSE 1, a Phase 3 clinical trial testing Vir Biotechnology’s experimental combination of tobevibart and elebsiran in adults…
CHOLANGITIS
NewsTrial testing golexanolone as PBC treatment delayed
A Phase 1b/2 trial testing Umecrine Cognition’s golexanolone in primary biliary cholangitis (PBC) patients with cognitive symptoms and fatigue has been delayed due to…
CHOLESTASIS
NewsABCB4 mutation ID’d as cause of woman’s recurrent cholestasis
A young woman in the U.S. who experienced recurrent cholestasis was later found, with the help of genetic testing, to have a mutation in…
FATTY LIVER DISEASE
NewsIcosabutate fails MASH Phase 2 trial but shows some benefits in liver
Northsea Therapeutics’ oral therapy candidate icosabutate was not superior to a placebo at resolving metabolic dysfunction-associated steatohepatitis (MASH) — a severe form of…
Recent Posts
- Being brave will serve my son with Alagille syndrome well
- Dosing starts in Phase 2 trial of oral therapy HU6 for MASH
- World Liver Day promotes small habits that can yield big health gains
- FDA puts pevifoscorvir sodium for hepatitis B on fast track
- Off-label fenofibrate improves liver health in PBC patients: Study